Composition controlling pharmacokinetics in the body
AssigneeKawasaki Institute of Industrial Promotion
InventorsKazunori Kataoka, Shigehito Osawa, Satoshi Uchida, Kotaro Hayashi, Anjaneyulu Dirisala, Kazuko Toh
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition that controls pharmacokinetics. Specifically, the present invention provides: a composition for controlling pharmacokinetics, the composition containing a polyvalent cation as an active ingredient; and a method for controlling pharmacokinetics using the polyvalent cation.
Claims28
A composition comprising a first polyvalent cation and a carrier encapsulating a drug,
- wherein the carrier is at least one selected from the group consisting of a virus, a liposome, and a micelle,
- wherein when the carrier comprises a second polyvalent cation, the second polyvalent cation is different from the first polyvalent cation,
- wherein the first polyvalent cation comprises a cationic polymer block and a polyethylene glycol (PEG) block,
- wherein the PEG block comprises a branched PEG that is branched at one site, has PEG chains extending from the branched site, and has a total average molecular weight of from 40 k Da to 100 k Da, and each PEG chain extending from the branched site independently has an average molecular weight of from 20 k Da to 60 k Da;
- wherein the cationic polymer block has an average polymerization degree of from 15 to 80, and has at least one cationic natural amino acid selected from the group consisting of histidine, tryptophan, ornithine, arginine and lysine, and cationic non-natural amino acid selected from the group consisting of aspartate and glutamate modified with a side chain shown by —(NH—(CH2)2)p—NH2, where p represents an integer of 1 to 5;
- and
- wherein the first polyvalent cation reduces clearance function of endothelial cells of liver sinusoidal endothelial cells and/or kidney vascular endothelial cells in a body received the composition.
A combination, comprising (i) a composition comprising a first polyvalent cation and (ii) a composition comprising a carrier encapsulating a drug,
- wherein the carrier is at least one selected from the group consisting of a virus, a liposome, and a micelle, wherein when the carrier comprises a second polyvalent cation, the second polyvalent cation is different from the first polyvalent cation,
- wherein the first polyvalent cation comprises a cationic polymer block and a polyethylene glycol (PEG) block,
- wherein the PEG block comprises a branched PEG that is branched at one site, has PEG chains extending from the branched site, and has a total average molecular weight of from 40 k Da to 100 k Da, and each PEG chain extending from the branched site independently has an average molecular weight of from 20 k Da to 60 k Da;
- wherein the cationic polymer block has an average polymerization degree of from 15 to 80, and has at least one cationic natural amino acid selected from the group consisting of histidine, tryptophan, ornithine, arginine, lysine, and a cationic non-natural amino acid selected from the group consisting of aspartate and glutamate modified with a side chain shown by —(NH—(CH2)2)p—NH2, where p represents an integer of 1 to 5;
- and
- wherein the first polyvalent cation reduces clearance function of endothelial cells of liver sinusoidal endothelial cells and/or kidney vascular endothelial cells in a body received the composition.
Dependencies are inferred from the claim text.